Cytokinetics (NASDAQ:CYTK) Releases Earnings Results, Misses Expectations By $0.17 EPS

Cytokinetics (NASDAQ:CYTK) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.17), Briefing.com reports. The company had revenue of $0.84 million during the quarter, compared to analyst estimates of $0.91 million. The business’s revenue for the quarter was down 81.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.38) EPS.

Cytokinetics Trading Down 1.9 %

Shares of NASDAQ CYTK opened at $64.02 on Friday. Cytokinetics has a 12-month low of $25.98 and a 12-month high of $110.25. The company has a market cap of $6.70 billion, a price-to-earnings ratio of -11.75 and a beta of 0.72. The stock’s 50 day simple moving average is $67.65 and its 200 day simple moving average is $61.68.

Insider Buying and Selling

In related news, Director John T. Henderson sold 5,000 shares of Cytokinetics stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $76.48, for a total value of $382,400.00. Following the sale, the director now directly owns 42,632 shares in the company, valued at approximately $3,260,495.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director John T. Henderson sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $76.48, for a total value of $382,400.00. Following the completion of the sale, the director now directly owns 42,632 shares of the company’s stock, valued at approximately $3,260,495.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 32,605 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $74.31, for a total value of $2,422,877.55. Following the sale, the executive vice president now directly owns 138,567 shares in the company, valued at approximately $10,296,913.77. The disclosure for this sale can be found here. Insiders sold a total of 96,318 shares of company stock worth $6,701,940 in the last three months. 3.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Oppenheimer dropped their price objective on shares of Cytokinetics from $107.00 to $106.00 and set an “outperform” rating on the stock in a research note on Thursday. JMP Securities dropped their price target on shares of Cytokinetics from $110.00 to $106.00 and set a “market outperform” rating on the stock in a research note on Thursday. Mizuho lowered their target price on Cytokinetics from $103.00 to $99.00 and set a “buy” rating for the company in a research note on Wednesday, March 6th. Needham & Company LLC reiterated a “buy” rating and issued a $108.00 price target on shares of Cytokinetics in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of Cytokinetics in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average price target of $81.60.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.